



## News Release

**Viapath Group LLP, announces the departure of Richard Jones, CEO and the appointment of Dougie Dryburgh, chief operating officer, as his successor**

**London, UK, 21 October 2016:** Viapath Group LLP, today announced that Richard Jones, CEO since 2011, will be leaving Viapath at the end of 2016 and the appointment of Dougie Dryburgh, currently chief operating officer, as his successor.

**Richard Jones** said: *"I am proud of what has been achieved at Viapath. Service delivery in our laboratories has been consistently good with an excellent record of meeting our operational performance and service quality metrics. We have invested more than ever in developing our workforce, improving our infrastructure and expanding our innovation programme. Our clinical, scientific and operational workforce is stronger than ever. We have expanded our customer base and increased our revenues consistently year-on-year. This is an excellent base from which to build, but as always there is still a great deal to do. The NHS faces enormous challenges, but Viapath is now well-placed to exploit the opportunity for growth that will benefit both NHS patients and our workforce."*

**David Bennett**, Viapath Chair said: *"I'd like to thank Richard for his contribution to Viapath. The organisation has a great potential and the board is grateful for his vision, energy and enthusiasm which has seen the organisation build the foundations for an exciting future. Pathology modernisation is now pivotal to the sustainability and transformation of the NHS as a whole. In that context the board and I are convinced Viapath has a secure and prosperous future ahead. I'm therefore delighted to welcome Dougie Dryburgh's appointment as our new CEO – he has already proven himself to be an excellent leader as Chief Operating Officer and is the ideal person to lead Viapath forward."*

**Dougie Dryburgh** said: *"I am really excited to be offered the privilege of leading Viapath as CEO. There is now a drive across the NHS to modernise diagnostics and build strong capabilities [using](#) fast-changing scientific technology, enabled by the [genomic](#) revolution. Viapath is uniquely well-placed to deliver this change as a majority NHS-owned specialist pathology provider."*

### **Editors Note:**

Viapath Group was previously known as GSTS Pathology LLP and rebranded as Viapath on 1 May 2014.

The organisation was created seven years ago by private and public sector investors and is now the fastest growing pathology company in the UK.

Pathology is vital to healthcare and it is estimated that 70-80% of all health care decisions affecting diagnosis or treatment involve a pathology investigation. Viapath provides pathology services to over 1200 customers having established a track record which is synonymous with high quality service delivery and value for money. The company has ambitious expansion plans over the coming years.

Viapath processes 26 million tests each year and its work touches thousands of lives every day.

For more information, visit [www.viapath.co.uk](http://www.viapath.co.uk) or follow us on Twitter @ViapathUK

**Press Information:**

Debbie Bowman | [Viapath](#)

Head of Internal Communication

Francis House, 9 King's Head Yard, London, SE1 1NA

E: [debbie.bowman@viapath.co.uk](mailto:debbie.bowman@viapath.co.uk)

[www.viapath.co.uk](http://www.viapath.co.uk)